Literature DB >> 10393964

Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption.

H Yoshitake1, S R Rittling, D T Denhardt, M Noda.   

Abstract

Osteopontin is one of the major noncollagenous bone matrix proteins produced by osteoblasts and osteoclasts, bone cells that are uniquely responsible for the remodeling of mineralized tissues. Osteoclasts express the alphavbeta3 integrin, which is one of the receptors for osteopontin. Recent knockout studies revealed that noncollagenous bone matrix proteins are functionally important in regulation of bone metabolism. However, the significance of the presence of osteopontin in in vivo has not been known. We report here that osteopontin knockout mice are resistant to ovariectomy-induced bone resorption compared with wild-type mice. Microcomputed tomography analysis indicated about 60% reduction in bone volume by ovariectomy in wild-type mice, whereas the osteopontin-deficient mice exhibited only about 10% reduction in trabecular bone volume after ovariectomy. Reduction in uterine weight was observed similarly in both wild-type and osteopontin-deficient mice, indicating the specificity of the effect of osteopontin deficiency on bone metabolism. We propose that osteopontin is essential for postmenopausal osteoporosis in women. Strategies to counteract osteopontin's action may prove effective in suppressing osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393964      PMCID: PMC22204          DOI: 10.1073/pnas.96.14.8156

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Characterization of the functional stages of osteoclasts by enzyme histochemistry and electron microscopy.

Authors:  O Fukushima; P J Bekker; C V Gay
Journal:  Anat Rec       Date:  1991-11

2.  Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts.

Authors:  A Miyauchi; J Alvarez; E M Greenfield; A Teti; M Grano; S Colucci; A Zambonin-Zallone; F P Ross; S L Teitelbaum; D Cheresh
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

3.  Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy.

Authors:  J A Lorenzo; A Naprta; Y Rao; C Alander; M Glaccum; M Widmer; G Gronowicz; J Kalinowski; C C Pilbeam
Journal:  Endocrinology       Date:  1998-06       Impact factor: 4.736

4.  The relationship of endogenous estrogen to bone density and bone area in normal postmenopausal women.

Authors:  J A Cauley; J P Gutai; R B Sandler; R E LaPorte; L H Kuller; D Sashin
Journal:  Am J Epidemiol       Date:  1986-11       Impact factor: 4.897

5.  The distribution of podosomes in osteoclasts cultured on bone laminae: effect of retinol.

Authors:  A Zambonin-Zallone; A Teti; A Carano; P C Marchisio
Journal:  J Bone Miner Res       Date:  1988-10       Impact factor: 6.741

6.  Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts.

Authors:  M A Horton; M L Taylor; T R Arnett; M H Helfrich
Journal:  Exp Cell Res       Date:  1991-08       Impact factor: 3.905

7.  Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse.

Authors:  R Felix; M G Cecchini; H Fleisch
Journal:  Endocrinology       Date:  1990-11       Impact factor: 4.736

8.  Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.

Authors:  S R Rittling; H N Matsumoto; M D McKee; A Nanci; X R An; K E Novick; A J Kowalski; M Noda; D T Denhardt
Journal:  J Bone Miner Res       Date:  1998-07       Impact factor: 6.741

9.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice.

Authors:  P Soriano; C Montgomery; R Geske; A Bradley
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

10.  Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.

Authors:  V Poli; R Balena; E Fattori; A Markatos; M Yamamoto; H Tanaka; G Ciliberto; G A Rodan; F Costantini
Journal:  EMBO J       Date:  1994-03-01       Impact factor: 11.598

View more
  92 in total

Review 1.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  When developmental biology meets human pathology.

Authors:  G Karsenty
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

3.  Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification.

Authors:  Susan A Steitz; Mei Y Speer; Marc D McKee; Lucy Liaw; Manuela Almeida; Hsueh Yang; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

4.  Osteopontin deficiency enhances parathyroid hormone/ parathyroid hormone related peptide receptor (PPR) signaling-induced alteration in tooth formation and odontoblastic morphology.

Authors:  Maki Morishita; Noriaki Ono; Kentano Miyai; Tomomi Nakagawa; Ryo Hanyu; Masashi Nagao; Paksinee Kamolratanakul; Takuya Notomi; Susan R Rittling; David T Denhardt; Henry M Kronenberg; Yoichi Ezura; Tadayoshi Hayata; Tetsuya Nakamoto; Masaki Noda
Journal:  Tissue Cell       Date:  2011-04-21       Impact factor: 2.466

Review 5.  Bone matrix proteins: their function, regulation, and relationship to osteoporosis.

Authors:  Marian F Young
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

Review 6.  Matrix proteins.

Authors:  Caren M Gundberg
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

7.  Upregulation of osteopontin by osteocytes deprived of mechanical loading or oxygen.

Authors:  Ted S Gross; Katy A King; Natalia A Rabaia; Pranali Pathare; Sundar Srinivasan
Journal:  J Bone Miner Res       Date:  2004-10-11       Impact factor: 6.741

Review 8.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

9.  Stability of mRNA influences osteoporotic bone mass via CNOT3.

Authors:  Chiho Watanabe; Masahiro Morita; Tadayoshi Hayata; Tetsuya Nakamoto; Chisato Kikuguchi; Xue Li; Yasuhiro Kobayashi; Naoyuki Takahashi; Takuya Notomi; Keiji Moriyama; Tadashi Yamamoto; Yoichi Ezura; Masaki Noda
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

10.  The first intron of the human osteopontin gene contains a C/EBP-beta-responsive enhancer.

Authors:  Francesca Giacopelli; Nadia Rosatto; Maria Teresa Divizia; Roberto Cusano; Gianluca Caridi; Roberto Ravazzolo
Journal:  Gene Expr       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.